Antibiotikaresistenta S aureus ger ökad dödlighet och dyrare sjukvård

Lakartidningen

Volumn 104, Issue 42, 2007, Pages 3052-3056

  Melander, Eva ^a   Burman, Lars G ^b   Cars, Otto ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; BACTEREMIA; COMPARATIVE STUDY; DRUG COST; DRUG EFFECT; ECONOMICS; EUROPE; HEALTH CARE COST; HUMAN; IMMUNOLOGY; INFECTION CONTROL; MORTALITY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; HEALTH CARE COSTS; HUMANS; INFECTION CONTROL; METHICILLIN RESISTANCE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 35848935181     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987;9(6):1065-78.
2. Verhoef J, Beaujean D, Blok H, Baars, A, Meyler A, van der Werken C, et al. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999;18:461-6.
3. Johnson AP, Auchen HM, Cavendish S, Ganner M, Wale MC, Warner M, et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother. 2001;48:143-4.
4. Moore PC, Lindsay JA. Molecular characterisation of the dominant UK methicillin-resistant Staphylococcus aureus strains, EMRSA-15 and EMRSA-16. J Med Microbiol. 2002;51:516-21.
5. Working party report. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J Hosp Infect. 1998;39:253-90.
6. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother. 2005;56:455-62.
7. Crowcroft NS, Catchpole M. Mortality from methicillin resistant Staphylococcus aureus in England and Wales: analysis of death certificates. BMJ. 2003;325:1390-1.
8. Haglind E, Brantevik Å, Friman S, Jertborn M, Rödjer S, Seeberg S. Bekämpningen av meticillinresistenta stafylokocker på Sahlgrenska. Framgångsrikt kontrollprogram har hävt MRSA-utbrottet. Läkartidningen. 2001;98(47):5312-3.
9. European Antibiotic Resistance Surveillance System: annual report 2005. http://www.rivm.nl/earss
10. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36: 53-9.
11. Reed SD, Friedman JY, Engemann JJ, Griffiths RJ, Anstrom KJ, Kaye KS, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2005;26(2):175-83.
12. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166-74.
13. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005;52:113-22.
14. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust. 2001;175(5):264-7.
15. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999;20(6):408-11.
16. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol. 2004;25(5): 425-30.
17. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Contr Hosp Epidemiol. 2001;22(2):99-104.
18. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis. 2004;10(6):1125-8.
19. Björholt I, Haglind E. Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital. Eur J Clin Microbiol Infect Dis. 2004;23:688-95.
20. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. Health Technol Assess. 2003;7(39):1-194.